Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Adam's Take

Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic

By Adam Feuerstein

FDA
Adam's Take

FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility

By Adam Feuerstein

lung caner jan 20
Biotech

Relay Therapeutics, focused on solid tumors, seeks to raise $250M in IPO

By Jonathan Saltzman — Boston Globe

Adam's Take

A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it

By Adam Feuerstein

IMMUNOTHERAPY lab
Biotech

With a clinical hold, off-the-shelf CAR-T hits a new safety concern

By Damian Garde

Novavax researchers
Biotech

Novavax, maker of a Covid-19 vaccine, is backed by Operation Warp Speed

By Helen Branswell

govt. money
Biotech

Venter Institute, Yumanity, and other biopharma companies among recipients of PPP loans

By Kate Sheridan

mammograms_CA
Biotech

Immunomedics’ breast cancer drug delays tumor growth, prolongs survival in clinical trial

By Adam Feuerstein

purple lungs ct
Biotech

Bellus Health suffers setback with clinical trial failure of chronic cough drug

By Adam Feuerstein

Covid-19 vaccine testing ethics
Biotech

Inovio claims positive results on Covid-19 vaccine but critical data are missing

By Damian Garde and Adam Feuerstein

Scorecard
Biotech

The biotech scorecard for the third quarter: 14 stock-moving events to watch

By Adam Feuerstein

Remdesivir vials in bags
Biotech

How Gilead’s remdesivir price could come back to haunt the drug industry

By Damian Garde

Liver illustration
Biotech

FDA rejects Intercept Pharma’s drug for NASH

By Adam Feuerstein

Remdesivir vial in bag
Biotech

Gilead announces long-awaited price for Covid-19 drug remdesivir

By Matthew Herper

Colorful DNA molecule
Biotech

Two patients die in Audentes gene therapy study, heightening concerns over high-dose treatments

By Matthew Herper

Biotech

Zogenix wins approval for new drug to treat rare type of childhood epilepsy

By Adam Feuerstein

Biotech

STAT Webinar: Targeted cancer drugs: What’s on the market? What’s in the pipeline?

By Damian Garde

human T cells in culture
Biotech

Engineering a better immunotherapy to outwit cancer — and launch a biotech

By Elizabeth Cooney

Biotech

Yumanity Therapeutics, Merck strike deal aimed at developing new medicines for neurodegenerative disease

By Adam Feuerstein

Biotech

STAT+ Conversations: The Readout LOUD, Live!

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

Fatty Liver
Biotech

As approval decision nears, fate of Intercept’s NASH drug clouded by murky FDA review delays

By Adam Feuerstein

doc consulting patient
Biotech

Myovant endometriosis drug meets its goal in a second late-stage trial, company says

By Elizabeth Cooney

Unicorn Stocks
Biotech

Sana Biotechnology, the secretive startup, lays (some) cards on the table

By Kate Sheridan

Blood sugar monitor - finger stick
Biotech

A Chinese drug maker scores a big clinical trial win with a novel diabetes therapy

By Jonathan Chan

Man coughing
Biotech

A crucial study of Bellus Health’s chronic cough drug reads out soon. Here’s what you need to know

By Adam Feuerstein

illuminated c. difficile
Biotech

Finch touts positive results for its microbiome pill for C. diff infections  

By Kate Sheridan

Biotech

Court invalidates Biogen’s patent on blockbuster multiple sclerosis drug

By Adam Feuerstein

Liver fibrosis IC
Health

CAR-T cells, better known as cancer drugs, show promise against aging in lab mice

By Sharon Begley

MORE Red Blood Cells
Biotech

BioMarin’s hemophilia gene therapy continues to prevent bleeding at four years

By Matthew Herper and Damian Garde

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy